Safehold Inc. announced its Q3 2026 financial results, reporting revenue of $118.7 million and net income attributable to common shareholders of $28.8 million, with earnings per share at $0.41. The company closed $38 million in new ground lease originations and saw its estimated unrealized capital appreciation rise to $9.9 billion. Despite recent market volatility due to rising rates, Safehold remains confident with strong customer engagement, ample liquidity, and a long-term liability structure. The company continues to innovate in the ground lease market, aiming to provide stable income and capital growth for shareholders.
Safehold's Q3 2026 results provide context for readers following real estate markets. For readers following real estate stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:21 WIB: out of 47 priced US real estate stocks, 21 rose and 26 fell. Notable movers include JAN at USD 29.55 (+3.87%), WY at USD 20.59 (-3.29%), and OPEN at USD 1.75 (-3.06%) with a typical hold time on Pluang of 34 days and order activity of 44% Sell / 56% Buy.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
